We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Solo titulares de alta señal — eventos macro, earnings, M&A, regulación. Listicles y clickbait de analistas filtrados por defecto. Refrescado cada hora.
Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
An $83,400 annual paycheck sits comfortably above the U.S. median household income of roughly $80,610. Replacing that income with a portfolio, no employer required, is the question this article answers. The basic formula is income target divided by yield equals capital required. The more important issue is what changes across three yield tiers, and why ... A $1.5 Million Portfolio That Quietly Pays You $83,400 a Year, No Job Required
Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both entered 2026 with fresh distributions and updated holdings. The two funds chase dividends through very different rule sets, and the gap between them is wider than the surface suggests. Quality Screen vs. Yield ... Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain
Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
By Karen Roman Oncolytics Biotech Inc. (Nasdaq: ONCY) said it has new data showing the use of pelareorep in metastatic colorectal cancer has a 19.5-month median duration of response compared to […]
Bristol-Myers Squibb, NYSE:BMY, has launched a new patient-focused "Won't Lose" media campaign ahead of the FIFA World Cup 2026. The campaign highlights the company’s focus on breakthrough medicines and resilience in the fight against serious diseases. The initiative is set to run nationwide across digital and social platforms and will feature high profile sports personalities. Bristol-Myers Squibb, NYSE:BMY, is putting fresh attention on its brand with "Won't Lose," a broad media effort...
Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash
If you are asking whether Bristol-Myers Squibb at around US$56.95 is offering fair value or a potential bargain, the starting point is to look past the headline share price and into how it stacks up against several valuation checks. The stock has had mixed returns, with a 2.2% decline over the past week and a 4.4% decline over the last month, but it is up 6.5% year to date and 25.7% over the past year, which may change how investors are thinking about both risk and opportunity. Recent...
BioNTech (NasdaqGS:BNTX) has started five additional pivotal oncology trials in collaboration with Bristol Myers Squibb. The company has expanded its oncology pipeline with new candidates entering later stage development. BioNTech plans to consolidate its manufacturing footprint to support operational efficiency and R&D investment. BioNTech, known for its mRNA technology, is pushing further into oncology as it works with Bristol Myers Squibb on multiple pivotal studies. For readers tracking...
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
Cytokinetics stock surged Tuesday on positive results in a key heart disease where its chief rival, Bristol's Camzyos, previously failed.